Navigation Links
QRxPharma Releases Additional Phase 3 Data for Q8003IR 'Dual Opioid' Pain Therapy
Date:5/22/2008

surgery and prior to the first 12mg/8mg dose of Q8003IR, the baseline patient pain intensity (PI) scores averaged 6.6 out of 10 units -- with 10 being the most severe on the Numerical Pain Rating Scale. Analgesic effects as reflected in the maximum pain improvement (PI) for the 12mg/8mg dose of Q8003IR yielded a 2 unit reduction of PI (decreasing patient scores to 4.6) versus a 0.14 unit increase of PI for placebo-treated patients. Placebo patients were treated with ibuprofen, a non-opioid analgesic.

The mean time to confirmed perceptible pain relief for Q8003IR was 42 minutes compared to 4.4 hours for placebo. The duration time of analgesic effect was 6.6 hours for Q8003IR versus 2.8 hours for placebo.

The 12mg/8mgdose data demonstrated that Q8003IR was well tolerated, with a low rate of patient withdrawal (8% discontinuing use due to adverse events and 6% discontinuing use due to efficacy failure) compared to placebo (with 2% discontinuing use due to adverse events and 25% discontinuing use for efficacy failure). Only 2% of 12mg/8mg Q8003IR treated patients experienced somnolence, and no incidences of euphoria were reported. The low level of somnolence and absence of euphoria reported were unexpected outcomes compared to what is typically seen with morphine or oxycodone. The significance of these observations will need to be confirmed in future studies that provide a direct data comparison.

All patients exhibited acceptable respiratory rates with reduction in blood oxygen levels occurring in less than 2% of those on the preferred dose of Q8003IR. Typical of opioid drugs, nausea and vomiting were the most common adverse events. Of patients receiving the 12mg/8mg dose, 56% experienced mild to moderate nausea that diminished over the first few hours of treatment; no incidences of severe nausea were reported. 32% of patients reported vomiting with initial dosing (18% mild to moderate and 14% severe). 20% of patients experienced mild to moderate di
'/>"/>

SOURCE QRxPharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
2. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
3. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
4. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
5. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
6. Immunosyn Corporation Releases SF-1019 Study Results
7. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
8. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
9. CEL-SCI Corporation Releases Letter to Shareholders
10. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
11. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , Boston Scientific to acquire leading male urology ... $1.65 billion, with $1.6 billion in upfront cash ... Health business , Divestiture furthers Endo,s strategic ... Endo International plc (NASDAQ: ENDP ) (TSX: ... with Boston Scientific (NYSE: BSX ), under which ...
(Date:3/2/2015)... , March 2, 2015  BioMed Realty Trust, Inc. ... recaptured approximately 313,000 square feet of space in the ... in the world through the termination of Vertex Pharmaceuticals, ... effective February 28, 2015. BioMed Realty will ... will immediately begin to reposition the properties to meet ...
(Date:3/1/2015)... -- An innovative interventional radiology treatment has been found ... their headaches, according to research being presented at ... Annual Scientific Meeting . Clinicians at Albany Medical ... State College in Saratoga Springs used a treatment ... give patients enough ongoing relief that they required ...
Breaking Medicine Technology:Endo Announces Divestiture of American Medical Systems' Men's and Prostate Health Businesses to Boston Scientific 2Endo Announces Divestiture of American Medical Systems' Men's and Prostate Health Businesses to Boston Scientific 3BioMed Realty Gets Back 313,000 Square Feet Of Valuable Real Estate In Cambridge Innovation District 2BioMed Realty Gets Back 313,000 Square Feet Of Valuable Real Estate In Cambridge Innovation District 3Image-guided treatment shown to break the migraine cycle 2Image-guided treatment shown to break the migraine cycle 3Image-guided treatment shown to break the migraine cycle 4
... ConvaTec Healthcare, a world-leading developer, manufacturer and marketer ... today announced that in connection with a refinancing of ... facilities and in combination with new senior secured credit ... Notes and Senior Notes. The offering of the new ...
... -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... in-vitro diagnostic ("IVD") company, today announced that its ... ("GP Medical") and Beijing Yuande Bio-Medical Engineering Co., ... 415th, respectively, in the Deloitte Technology Fast 500 ...
Cached Medicine Technology:ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 2ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 3China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Program 2
(Date:3/1/2015)... (PRWEB) March 01, 2015 Women’s Excellence ... Obstetric terms on their website. There are over ... all the time. , “This gives our patients a ... use medical terminology that they may not understand. With this ... (which is mobile optimized) and find terms and phrases that they ...
(Date:3/1/2015)... NC (PRWEB) March 01, 2015 Researchers ... reason that so many sheet metal workers contract malignant ... this new report on its website. Click here ... Center for Construction Research and Training monitored 17,345 sheet ... a disproportionate number of them died of mesothelioma ...
(Date:3/1/2015)... Indiana (PRWEB) March 01, 2015 ... statewide Network Service Provider, announces NewWays Networking, LLC ... “By working with IFN, NewWays is well ... meet client’s demand for Internet bandwidth in rural ... , According to Cory Childs IFN Enterprise ...
(Date:3/1/2015)... February 28, 2015 CrossFit Attollo is a ... are offering a special discount to new members. Now ... for a three month contract will receive their fourth month ... would cost members $440. The three month contract is ... and then the fourth month comes in at only $55. ...
(Date:2/28/2015)... February 28, 2015 In a recent ... of Game Change Athlete Development Services ... about the benefits of athlete development and player engagement ... the unique challenges that athletes face and how off-field ... success. , Fletcher became involved in athlete development issues ...
Breaking Medicine News(10 mins):Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:NewWays Networking Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3
... Scientists have identified the receptor in cells of the peripheral ... to sense cold. ,The finding, reported on-line ... the key mechanisms by which the body detects temperature sensation. ... mediates how the body experiences intense stimuli temperature, in ...
... (FDA) today approved Torisel (temsirolimus) for the treatment of a ... carcinoma. Torisel was approved based on a study that ... renal cell carcinoma. The drug is an enzyme inhibitor, a ... ,'We have made significant advances in the battle ...
... is only a pretext for multinational corporations to take control ... in US charge. With sales of over $35 billion ... it takes to buy up pristine springs in some of ... Nestl, which controls one-third of the U.S. market and sells ...
... combined with sulphur to improve its overall strength and durability. ... to reform and reuse old tyres. The only way ... a process that releases heavy metals and other pollutants and ... and colleagues at Swansea University, UK, have shown that spinning ...
... will have a new -- virtually pain free -- ... Health System (SJMHS) announced today it will begin treating ... Wednesday, June 6th. ,This advanced radiosurgery system ... previously inoperable tumors, with astounding accuracy and with little ...
... to emergency needs and low donor turnout. The American Red ... can, to donate blood. ,As of this ... Red Cross had no units of Type O-negative -- the ... below a one-day supply. ,Shortages of Type O-negative ...
Cached Medicine News:Health News:Detecting Cold, Feeling Pain: Study Reveals Why Menthol Fresh 2Health News:Detecting Cold, Feeling Pain: Study Reveals Why Menthol Fresh 3Health News:FDA: New Drug for Advance Kidney Cancer 2Health News:Multinationals Exploit Groundwater Sources, and People Suffer 2Health News:Multinationals Exploit Groundwater Sources, and People Suffer 3Health News:Multinationals Exploit Groundwater Sources, and People Suffer 4Health News:Multinationals Exploit Groundwater Sources, and People Suffer 5Health News:Advanced Cancer Treatment Brings New Hope to Michigan Patient 2
DMSO-resistant microplate sealing film...
Amplification Tape 96 featuring 3M adhesive technology. Good optical quality. Minimal autofluorescence. Certified RNase and DNase free....
Empore Sealing Tape Pads are ideal for covering a 96 well plate during storage or transfer to another work station. Not intended for use with auto-injectors....
... Microseal 'B' seals provide an adhesive-based ... microplates. The aggressive adhesive layer ensures secure ... cycling, and tight sealing during thermal cycling ... heated lid. The perforated end-tabs can be ...
Medicine Products: